Back to News
Market Impact: 0.2
Argus Research Upgrades Regeneron Pharmaceuticals to Buy from Hold
Source: Nasdaq
Healthcare & BiotechAnalyst Insights
Argus Research upgraded Regeneron Pharmaceuticals (NASDAQGS: REGN) to Buy from Hold on October 1, 2026. The rating change is a positive signal for investor sentiment toward the biotechnology company, though the article provides no price target, earnings revisions, or fundamental rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
REGN0.55
More News
- Sanofi to pay Regeneron up to $8 billion to add new antibodies under Dupixent partnership
- Jefferies raises Regeneron stock price target to $930 on partnership
- Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
- Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée
- Why the media’s whisper campaign about a Goldman Sachs change at the top is misleading gossip, at best
- Europe’s winter energy crunch may already be underway. Two U.S. stocks that may benefit